Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Martinek, M; Gwechenberger, M; Scherr, D; Steinwender, C; Stühlinger, M; Pürerfellner, H; Roithinger, FX; Fiedler, L; Arbeitsgruppe Rhythmologie der Österreichischen Kardiologischen Gesellschaft.
[S1 guideline - Austrian consensus for anticoagulation in the context of atrial fibrillation ablation].
Wien Klin Wochenschr. 2018; 130(Suppl 1):1-8 Doi: 10.1007/s00508-017-1310-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Scherr Daniel
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: In summary, uninterrupted oral antikoagulation can be recommended, with different recommendation classes and levels of evidence, for both, VKA and NOAC therapy, in the framework of PVI. Even with low CHA₂DS₂ VASc scores, OAK is indicated 3-4 weeks before and 8 weeks after the procedure. Periinterventional bridging with heparins should be avoided due to increased bleeding events.The present Consensus provides recommendations on the current state of knowledge and has been prepared exclusively by members of the Rhythmology Working Group of the Austrian Cardiological Society who have great practical experience in catheter ablation and peri-interventional OAK in patients with atrial fibrillation. Publication of new randomized and controlled studies on the subject are expected in the coming months, so that there will certainly be changes in the recommendations. The Rhythmology Working Group of the Austrian Cardiological Society will strive to keep this S1 guideline regularly up to date. We hope that this consensus is used to increase the safety for patients undergoing PVI and to provide physicians with a homogeneous approach in Austria.
Find related publications in this database (Keywords): Ablation; Atrial fibrillation; Vitamin K antagonists (VKA); Non-vitamin k oral anticoagulants (NOAC); Consensus